ReviewAnnals of medicine2026
LncRNA H19 as a key regulator in biliary atresia: insights into pathogenesis and potential therapeutic targets.
Review in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiliary atresia (BA) is a devastating cholangiopathy, characterized by onset of persistent cholestatic jaundice during the neonatal period. The etiology of BA remains incompletely understood and is considered multifactorial. Recent evidence has identified that the long non-coding RNA H19 (H19) is among the critical regulators involved in this pathological process. This review summarizes the current understanding of the H19 in the pathogenesis of BA. DISCUSSION: The pathogenesis of BA is considered to be closely associated with impaired biliary epithelial barrier function. This barrier defect renders cholangiocytes more susceptible to injury and promotes bile acid retention. Within this pathological microenvironment, multiple factors such as bile acids and estrogen significantly upregulate H19 expression, with its level showing a positive correlation with the severity of BA. Up-regulated H19 is predominantly enriched in cholangiocytes and can be delivered to adjacent hepatocytes, hepatic stellate cells, macrophages, and liver sinusoidal endothelial cells, where it orchestrates cellular activities
conclusionThis review comprehensively and systematically delineates the key regulatory network of H19 in BA, highlighting its translational potential as a novel therapeutic target and laying a theoretical foundation for future mechanistic exploration and clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.